Objective: Cachexia and weight loss are frequently seen in cancer patients. We investigated lipid metabolism to elucidate a metabolic basis for adequate nutrition of cancer patients. Design: Lipid metabolism was assessed by indirect calorimetry and triglyceride clearance rates after randomised injection of a lipid bolus (long-chain triglycerides (LCT) or medium-chain triglycerides (MCT) during an euglycemic clamp protocol in cancer patients. Setting: Rudolf-Virchow Krankenhaus, Berlin, Germany. Subjects: Eighteen patients were included. Twelve patients had upper gastrointestinal cancer: a weight stable cancer group (Caws, n 6) with a body mass index (BMI) of 22.9 AE 1.7 kgam 2 and a weight losing cancer group (Cawl, n 6) with a mean weight loss of 7.4 AE 3.1 kg or 11% of the initial body weight during the previous three months (present BM1 21.8 AE 0.8 kgam 2 ). The data were compared with six control patients with benign gastrointestinal diseases (BMI 25.0 AE 0.8 kgam 2 ). Main outcome: Cancer patients had an increased basal lipid oxidation rate that was more pronounced in Cawl ( 92% vs 42% in Caws; P`0.01 and 0.05 vs controls, respectively). Utilisation of LCT was increased in cancer patients, this was most pronounced in Cawl ( 150 vs 65% in Caws; P`0.01 and 0.05, respectively). Metabolically, there were no differences in the utilisation of LCT and MCTaLCT containing lipid emulsions. Conclusions: Cancer patients have an increased lipid oxidation and an enhanced utilisation of exogeneous lipids. This is most pronounced in Cawl. To prevent further weight loss or to increase body weight, they should increase their fat intake. In contrast, fat-reduced or prudent diets seem to be inadequate for the nutrition of cancer patients.
Introduction
Cancer cachexia describes anorexia and a progressive, involuntary weight loss (Heyms®eld and McManus, 1985; Kern and Norton; DeBlauw et al, 1997) . A large proportion of the weight loss is explained by reduction in fat mass, which may be up to 80% of the weight loss. Although often associated with preterminal disseminated disease, cachexia may also be present in early stages of tumour growth before any signs or symptoms of malignancy appear. A decline of food intake relative to energy expenditure explains part of cancer-associated weight loss. In addition, abnormalities of host metabolism lead to mobilisation and ineffective repletion of host tissues during nutritional support. Deranged fat metabolism with increased lipolysis, decreased or increased lipogenesis, increased turnover rates of free fatty acid (FFA) and glycerol, and enhanced FFA-triacylglycerol recycling have been reported to add to the depletion of fat mass in cancer patients (Shaw and Wolfe, 1987) .
With the advent of parenteral nutrition it is possible to provide adequate nutrient supply in malnourished cancer patients. However, even intensive nutritional support seldom leads to a recovery of the nutritional state in cancer patients (Brennan, 1981; Klein et al, 1986) . This may be explained by the failure of the current nutritional regimens to reverse completely the abnormalities and meet the demands of host metabolism. Present nutritional regimens mimic the concepts of`healthy nutrition', that is, glucose is the main source of energy. However, it is unclear whether`healthy nutrition' is adequate to cope with nutritional derangements in cancer patients. With respect to the metabolic basis of cancer cachexia, increased rates of lipolysis and FFA-turnover might suggest increased lipid needs. However, we do not know whether cancer patients can adequately metabolise exogenous lipids. We therefore investigated the metabolism of different lipid emulsions medium-chain triglyceridesalong-chain triglycerides (MCTaLCT) and LCT) using a standardised approach for studying lipid utilisation.
Methods

Subjects
Eighteen male hospitalised patients were included into the study (for details see Table 1 ). Twelve patients had histologically proven cancer of the esophageous or phar-yngeal cancer. Six cancer patients had a weight loss (Cawl) of 11% (range 5 ± 17%) of body weight (bw) in the last three months before admittance. The other six cancer patients were considered as weight stable (Caws, that is, they remained within AE 4.9% of their bw within the six months previous to the study). The control group consisted of six weight stable patients with benign gastrointestinal disorders (four with peptic ulcer disease, two with diverticulosis). All patients were judged to be free of other metabolic or endocrine disorders, they had no history of systemic illness, hypertension, ischaemic heart disease and there was no clinical evidence of infection. None was taking medication known to alter glucose, protein or lipid metabolism. All subjects were on standard hospital diet including 50 ± 55% carbohydrates, 35 ± 37% fat and 10 ± 15% protein. The patients had smoking habits of about one pack of cigarettes per day. The had not drunk alcohol for at least three weeks before entering the study. A speci®c cancer therapy had been performed in one patient six months before the study. Disease history varied between one and ten months. In the control group, four patients with peptic ulcer disease received a proton pump inhibitor (omeprazole 40 mgad). All patients were fully informed about the purpose, as well as the study protocol, and gave their written consent. The protocol was approved by the respective institutional ethical committees of the VirchowKlinikum, Medizinische Fakulta Èt der Humboldt Universita Èt zu Berlin.
Experimental design
Two different protocols were performed on 2 d with an interval of at least 48 h. All studies were started in the morning at 7 a.m. after a 12 h overnight fast. Patients were studied under standardised conditions in a comfortable warm room with the subjects supine. For blood sampling a small polyethylene catheter was inserted into a hand vein, and the hand was placed into a heated box (60 C) for sampling arterialised blood. A second catheter was inserted on a contralateral antecubital vein for infusion of glucose (20% solution) and insulin (Human-Altinsulin, H-Insulin, Hoechst, Germany).
Respiratory exchange measurements
Oxygen consumption, carbon dioxide consumption, energy expenditure and respiratory quotient were recorded continuously every minute with indirect calorimetry using a canopy system (Deltatrac, Metabolic Monitor, Datex Instruments, Finnland). Gas sensors were calibrated before each measurement with standard gases provided by the manufactures. The machine was validated by an alcohol burn test every other month. Measurements were started between 7 and 8 a.m. in a metabolic ward. On the day before, the patients had their last meal between 6 and 7 p.m. After calibration and a stabilisation period of 30 min oxidation rates of glucose and fat were calculated from means of VO 2 and VCO 2 during the basal state (30 ± 60 min). Then the euglycemic clamp protocol was started. A stable period of 30 min (that is between 45 and 75 min of the clamp protocol) was used for data analyses (for details of indirect calorimetry see Mu Èller et al, 1988 and . Calorimetric measurements were continued after the lipid bolus had been injected up to the end of the protocol. The total duration of the clamp protocol 195 min. Variation in the results from the technique was calculated based on ®ve repeated measurements of propan combustion and was found to be b 4%. The within-test variation of the 5-min oxygen consumption values was`7.5%. Daily variances between individuals based on test ± retest measurements in a subgroup of ten weight stable and healthy subjects performed on three different days within a 14 d period were below 6%. Overnight urinary nitrogen excretion (Nu) as well as nitrogen excretion over the whole clamp period were determinated and the NPRQ (non-protein respiratory quotient) was calculated. Nu was analysed using a chemiluminisence analyser (ANTEK 720 nitrogen detector, ANTEK Instruments Inc., Houston Texas, USA). Calculation of energy expenditure and substrate oxidation rates from VO 2 , VCO 2 , and Nu were performed as described previously (Mu Èller et al, 1988; .
Hyperinsulinemic euglycemic clamp
The aim of the euglycemic clamp technique is to maintain euglycemia during a constant insulin and glucose infusion. The insulin solution was freshly prepared (diluted in 0.9% NaCl using 4 ml of the patients' own blood) and infused starting with an insulin bolus and decreasing the doses in a logarithmically falling fashion during the ®rst 10 min of this period. The maintenance dose was 1 mUakg bwamin. A variable infusion rate of glucose (20%) which was computed at 5 min intervals was used to maintain basal serum glucose concentration (De Fronzo et al, 1978; Mu Èller et al, 1988 Mu Èller et al, , 1991 .
Intravenous fat tolerance test
Patients were randomised with respect to the different lipid emulsions, MCTaLCT 20% (1 g 1.57 mmol 153 g glycerol: Lipofundin MCT 20%, B.Braun, Melsungen, Germany) at day 1 or LCT 20% (1 g 1.14 mmol 112 g glycerol: Lipoveno Ès 20%, Fresenius, Bad Homburg, Germany) at day 2. A lipid bolus of 0.1 gakg bw was injected intravenously within 1 min after a euglycemic clamp period of 75 min. Lipid kinetics were followed for 120 min.
Assessment of body composition
Body composition was estimated using bioelectrical impedance analysis (BIA, Body-Composition Analyzer, Danninger Medical, Neuss, Germany). Measurements were Cawl weight losing cancer patients; caws weight stable cancer patients. *P`0.05 vs controls.
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Laboratory methods
Arterialised blood samples were obtained before (n 3), during stable clamp conditions (n 3), and 5, 15, 30, 60, 90, and 120 min after the lipid bolus injection, allocated into appropriate tubes and immediately placed on ice. Blood for immunreactive insulin and C-peptide determination was collected, centrifuged, and immediately frozen at 7 80 C for subsequent analysis. Serum glucose was measured every 5 min during the study by glucose peroxidase reaction (Beckman Glucose Analyzer 2, Beckman Instruments, USA). Serum C-peptide (Serono Diagnostics, Biodata, Rome, Italy) and insulin (Pharmacia Diagnostics, Upsala, Sweden) were determinated by radioimmunoassays (RIA). Serum triglycerides and cholesterol were estimated by enzymatic determination (GPO-PAP and CHOD-PAP System, Boehringer Mannheim, Germany). FFA were measured colorimetrically by NEFA-Test (NEFA C, Wako chemicals, Neuss, Germany). Ketone bodies were measured as described previously (Mu Èller et al, 1992) . Lipoproteins had been separated by ultracentrifugation and precipitation. Triglycerides and cholesterol were measured enzymatically in different lipoprotein fractions (Kohlmeier, 1986) .
Statistical analysis
Clamp-derived glucose disappearance was calculated as described previously (Mu Èller et al, 1988) . Triglyceride elimination rate, area under the curve (AUC, that is, the concentration of triglycerides in the systemic circulation as a function of time), and clearance rate were calculated following the principles of pharamocokinetics. The rate of elimination was determined by plasma concentration ± time curves. Systemic clearance was determined from the mass balance, that is, dose normalised by AUC assuming complete bioavailability and ®rst-order kinetics of elimination. The clearance rate is the volume of plasma which is freed of triglycerides accounting for elimination per unit of time and body weight. All group data are presented as means AE s.e.m. A Wilcoxon test, Kruskal ± Wallis-test, Mann-Whitney and Friedman test were used when appropriate. Statistical signi®cance was ascertained with P`0.05 and P`0.01.
Results
Nutritional indices
There were no signi®cant differences between all three patient groups regarding age, sex, height, and body weight (Table 1) . When compared with controls, cancer patients had a reduced absolute fat mass (Table 1) . When compared with controls and weight stable cancer patients ( Caws) weight losing cancer patients ( Cawl) also had a diminished body cell mass (Table 1) .
Metabolic data
There were no signi®cant differences in energy expenditure between the study groups before (resting energy expenditure REE; control 4.35 AE 0.50; Caws 4.48 AE 0.67; Cawl 4.35 AE 0.50 kJamin; n.s.) as well as during the clamp protocol (data not shown). Deviation between the measured and the calculated REE varied between 710 and 15% (mean 3.8 AE 8.4%) and no patient was considered to be hypermetabolic (that is, REE b 20% of the estimated value). When compared to controls basal respiratory quotient (RQ) was reduced in both cancer groups (control 0.91 AE 0.02; Caws 0.86 AE 0.02; Cawl 0.83 AE 0.01; P`0.01 vs controls). Cancer patients thus had a reduced basal glucose oxidation rate (control 21.4 AE 3.0; Caws 16.1 AE 4.2*; Cawl 13.3 AE 1.7 mMola kgFFMamin, P`0.01 vs controls) and an increased lipid oxidation rate (Figure 1 ). Basal levels of plasma FFA and ketone bodies (KB) were increased in Cawl but were unchanged in Caws (Figure 1 for FFA, b-hydroxybutyrate 0.266 AE 0.014, 0.302 AE 0.044 and 0.454 AE 0.084 mmolal* in controls, Caws and Cawl respectively, P`0.05 vs controls). When compared with controls basal plasma concentrations of triacylglycerides were lower in both cancer groups on both study days (control 2.12 AE 0.24; Caws 1.13 AE 0.09; Cawl 1.27 AE 0.12 mmolal**, P`0.01 vs controls). Basal plasma cholesterol was 6.01 AE 0.29 in control patients, and 5.24 AE 0.26 or 5.38 AE 0.24 mmolal, in Caws and Cawl, respectively (n.s.). Concomitantly, HDL-cholesterol was slightly reduced (n.s.) at unchanged LDL-cholesterol in cancer patients (data not shown).
During the clamp, similar amounts of glucose were infused to maintain euglycemia in all groups and in the different protocols (control 23.6 AE 5.5; Caws 28.8 AE 7.8; Cawl 22.2 AE 7.2 mmolakgFFMamin, n.s.). Variations in plasma glucose levels were less than 3% during the clamp period. Basal plasma concentrations of insulin (control 78.4 AE 21.7; Caws 73.5 AE 21.7; Cawl 50.4 AE 28.0 pmolal n.s.; reference range 35 ± 130 pmolal) and C-peptide (control 0.91 AE 0.25; Caws 0.70 AE 0.50; Cawl 0.88 AE 0.47 pmolal n.s.; reference range 0.4 ± 1.2 pmolal) did not differ between the groups and between both study days. During the hyperinsulinemic clamp serum insulin concentrations increased (control to 355 AE 75; Caws to 367 AE 124 and Cawl to 341 AE 82 pmolal; P`0.001 vs basal levels in all groups), whereas C-peptide concentrations were reduced to 70% of the pre-clamp value (data not shown). Both The lipid bolus did not affect the insulin induced glucose oxidation rates. After starting glucoseainsulin infusion plasma triacylglycerol concentrations were signi®cantly decreased in all patients and during both protocols (controls 1.85 AE 0.09 vs 1.76 AE 0.33 mmolal in the LCT or LCTaMCT protocol respectively, P`0.05 vs basal state; Caws 0.97 AE 0.09 vs 1.00 AE 0.02 mmolal, P`0.05 vs basal state and P`0,01 vs controls; Cawl 1.17 AE 0.15 vs 1.01 AE 0.11 mmolal, P`0.05 vs basal and P`0.01 vs controls) and increased after the bolus injection. Peak values reached 2.93 AE 0.14 (after LCT) or 3.76 AE 0.39 mmolal (after LCTaMCT) in controls 2.47 AE 0.21 or 2.90 AE 0.24 and 2.31 AE 0.17 or 3.04 AE 0.2 mmolal in Caws and Cawl, respectively. Thus higher peak values were observed after the lipid bolus in cancer patients (P`0.05 vs controls). When compared with the LCTbolus, levels of plasma triacylglycerides were higher after injection of a MCTaLCT fat bolus (P`0.05 for Caws and Cawl, respectively). After the peak, levels of plasma triacylglycerides fell rapidly. When compared to controls the decay rates were more pronounced in cancer patients (Table 2) . Thus, elimination rates of triglycerides were signi®cantly increased in both cancer groups (Table 2, Figure 2 ). Similar kinetics were observed for triglyceride rich lipoproteins (data not shown). There were no differences between both cancer groups. During the clamp, FFA and b-hydroxybutyrate decreased, but FFA increased again in response to the lipid bolus (peak values after lipidbolus vs values obtained during the clamp in control 131%; Caws 115%; Cawl; 131%; P`0.05 or 0.01 vs the previous period 45 ± 75 min of the clamp protocol, in all groups). Similar FFA-peak values and kinetics were seen on both days. Plasma ketone body concentrations decreased by 47, 64 and 57% (after MCTaLCT bolus) or 39, 74 and 43% (after LCT bolus) in controls, Cawl and Caws, respectively. The rate of lipid oxidation decreased by 38, 36 and 13% (after MCTaLCT bolus) and 44, 38 and 5% (after LCT bolus) in Cawl, Caws and controls, respectively (P`0.05 for Caws or Cawl vs. controls). During the clamp there were no relationships between the fall in lipid oxidation rate or in plasma ketone body concentrations and the clearance rate of exogenous lipids.
Discussion
Cancer cachexia is characterised by reduced fat stores (Table 1) . Metabolically this had been explained by an increased rate in lipolysis (DeBlauw et al, 1997) . The essential ®ndings of our present study were as follows:
cancer patients with normal body weight had an increased lipid oxidation rate which was more pronounced in a weight losing group ( Figure 1) ; using a standardised clamp protocol together with a lipid bolus utilisation of exogenous lipids was increased in cancer patients (Table 2, Figure 2) ; and there were no signi®cant differences in lipid clearance rates between weight losing and weight stable cancer patients and also after infusion of different lipid emulsions (that is, MCTaLCT and LCT-emulsions; Table 2, Figure 2 ).
The ®rst ®nding agrees with previous data on cancer patients reported by other authors (Brennan,1981 ; Selberg Lipid metabolism in cancer patients J Ko Èrber et al Sauerwein et al, 1988) . However, only one group of authors (Shaw and Wolfe, 1987) had compared the lipid oxidation rates in weight losing and weight stable cancer patients. In this study, lipid oxidation rate was markedly increased in weight losing cancer patients and the response to total parenteral nutrition (TPN) in terms of FFA oxidation was similar in septic and in cancer patients. The increased lipid oxidation rate is in accordance with our present data (Figure 1 ). However, up to now there have been no data (obtained during a standardised experimental protocol on lipid utilisation in normal weight cancer patients. In the study mentioned previously, there was an increase in FFA oxidation during a glucose-rich TPN. In terms of lipid kinetics weight losing cancer patients were not different from healthy volunteers. However, when compared to septic patients they were shown to have an impaired capacity to oxidise exogenous fat. This ®nding is contrary to our data: we found no differences between the groups with respect to`post-load' lipid oxidation and an increased lipid clearance rate in cancer patients (Table 2, Figure 2 ). The latter ®nding was more pronounced in weight losing cancer patients (Figure 2 ). It should be mentioned that: (1) our cancer patients were free of infections; (2) had normal body weights; and (3) we used a clamp protocol providing a metabolic steady state which seems to be suitable to detect speci®c changes in lipid metabolism.
Clinical and experimental data suggest reduced plasma lipoprotein lipase activity and synthesis in malignancyassociated weight loss (Vlassara et al , 1986; Noguchi et al,1991) . The latter ®nding suggests impaired clearance of exogenous lipids in cancer patients. This idea is questioned by our data. Comparing the kinetics of plasma triglycerides after infusion of MCTaLCT with LCT-emulsions suggests that lipid clearance rate is increased in response to the infusion of LCT-emulsions (Figure 2 ). Considering the differences in the molar amounts of lipids infused in our protocol (see methods, 1 g MCTaLCT 1.57 mmol vs 1 g LCT 1.14 mmol) the differences in the kinetics of the two emulsions may increase further. With respect to the metabolic fate it is tempting to speculate that exogenous lipids are mostly metabolised by non-oxidative pathways, that is, lipid storage. This will replenish the depleted lipid stores in cancer cachexia. This idea is supported by our ®ndings of unchanged lipid oxidation rates as well as unchanged plasma ketone body concentrations in response to lipid infusion (see results). The ®nding of a better utilisation of LCT emulsion in cancer patients then suggests that LCT are better substrates for lipid storage than MCTaLCT. In fact MCTaLCT are preffered substrates for lipid oxidation (Lutz et al,1989; Johnson et al, 1990) . However, lipid oxidation is reduced by insulinaglucose infusion (see results). Thus, differences in the clearance rates between MCTaLCT and LCT observed in our protocol may be explained by: (1) the clamp procedure; (2) different metabolic fates of LCT and MCT; and (3) the different degrees of depletion of fat stores in the different patient groups (Table 1 ).
The present data may have an impact on the nutrition of cancer patients. Since endogenous lipid oxidation and postprandial lipid utilisation were both increased in cancer patients (Figures 1 and 2) it is tempting to speculate that fat intake should be increased to meet the metabolic needs of (at least cachectic) cancer patients. This is contrary to the current concepts of enteral and parenteral nutrition, where about 50% of energy is derived from carbohydrates. This``traditional' regimen mimics the concept of a prudent diet. There is overwhelming evidence that a low fat or prudent diet has bene®ts for healthy subjects and contributes to cancer prevention. Since, however, it is known from clinical practice that cachectic patients most frequently fail to recover from malnutrition in response to carbohydrate-based nutrition, the metabolic value of the prudent diet is questionable for this patient group. Our data Lipid metabolism in cancer patients J Ko Èrber et al suggest that we should increase fat intake in cancer patients in order to meet their metabolic demands. With respect to parenteral nutrition we, therefore, recommend an infusion of up to 50% of energy as lipids. In clinical practice, this should be controlled by assessing plasma triglyceride concentrations.
